HSP90AB1 and prostate carcinoma: N-terminal HSP90 inhibition was associated with reduction in FN secretion in prostate cancer [37] and levels of HSP90 in the circulation were correlated with disease severity in patients with idiopathic pulmonary fibrosis (IPF) [38].